Identify your patient’s actionable lung cancer mutations
Guideline-recommended, blood-based mutation results within 72 hours.
What is the GeneStrat® test?
- Delivers guideline-recommended1, blood-based mutation results: EGFR, ALK, ROS1, RET, BRAF, and KRAS
- Results within 72 hours can reduce treatment delays and expedite clinical trial enrollment
- Drives treatment strategy and facilitates monitoring
- Measures circulating cell-free DNA and RNA using Droplet Digital™ PCR (ddPCR)
- Highly sensitive and specific mutation detection
- Clinically validated
Nearly 80% of patients currently do not have mutation results available at their initial oncology consult.
How do we change this paradigm with blood-based testing?
Source: Lim, C., et.al. 2015. Biomarker Testing and Time to Treatment Decision in Patients with Advanced Non-Small Cell Lung Cancer. Ann Oncol first published online April 28, 2015
Save time, Save tissue
BLOOD-BASED RESULTS WITHIN 72 HOURS EXPEDITE TIME TO TREATMENT IN AS
LITTLE AS 8 DAYS2 FROM DIAGNOSTIC BIOPSY.
Tissue-based Tumor Mutation Testing: Presentation to Treatment
GeneStrat Tumor Mutation Testing: Presentation to Treatment
Reference: 1. NCCN Guidelines 2. Bowling, et al. J Clin Oncol 36, 2018 (suppl; abstr e18519) 3. Hagemann, et al. Cancer. 2015;121:631-9. 4. Vidaver RM et al. J Oncol Pract 2016 Jun 3;12(6):e643-53
Accurate, actionable genomic results
|Available Mutations||Clinical Sensitivity||Clinical Specificity||Concordance||Treatment Implications|
|95.8%||100%||98.8%||May benefit from treatment with osimertinib, afatinib, erlotinib, gefitinib, or dacomitinib|
|86.7%||100%||96.4%||May benefit from osimertinib if previously treated with 1st or 2nd generation EGFR TKIs|
1, 2, 3
|85.0%||100%||92.0%||May benefit from treatment with alectinib, brigatinib, ceritinib, crizotinib, or lorlatinib, depending on previous therapies and other clinical factors|
G12C, G12D, G12V
|87.9%||100%||96.0%||KRAS mutations are associated with poorer prognosis|
CD74, SDC4, SLC34A2, EZR, TPM3
|—||100%||—||May benefit from treatment with crizotinib, ceritinib, or lorlatinib, depending on previous therapies|
KIF5B, CCDC6, TRIM33
|—||100%||—||May benefit from treatment with cabozantinib or vandetanib|
|—||100%||—||May benefit from dabrafenib + trametinib, vemurafenib, or dabrafenib|
Combined variant results
|90.9%||100%||97.0%||See implications listed above for each variant|
*Clinical sensitivity and specificity were not calculated for ROS1, RET, and BRAF due to availability of samples with rare mutations (ROS1, RET) and treatment-naïve samples (BRAF)
SEE OUR PUBLICATION DATA LIBRARY
We are committed to supporting your treatment strategies and improving the lives of patient’s with lung cancer.
SAVE TIME. 72-HOUR TURNAROUND.
SAVE TISSUE. ONE SIMPLE BLOOD DRAW.
TWO SIDES OF CANCER. GENOMIC & PROTEOMIC TESTING.
$0 OUT OF POCKET EXPENSE FOR MEDICARE AND MEDICAID PATIENTS.
Interested in ordering a test kit?CLICK HERE TO MAKE AN ONLINE KIT REQUEST